Latest news with #RCC
CTV News
a day ago
- Business
- CTV News
No deadline extension for businesses to conform to Bill 96 rules: Roberge
Quebec is turning down a request from business groups to extend the deadline to comply with provisions of Bill 96. Quebec is turning down a request from the Retail Council of Canada (RCC) and the Canadian Federation of Independent Business (CFIB) to extend the deadline to conform to new language laws. With just two days until provisions of Bill 96 come into effect, they say businesses need a 'reasonable delay' to iron out details and change all signs and labels, as per the government's initial commitment. 'The last thing we want to do is criticize a measure related to the protection of the French language. On the contrary, we want to defend, promote and spread the French language. But to achieve this, we must also provide retailers with a clear and realistic path forward,' Michel Rochette, president of the RCC for Quebec, said in a news release. The CFIB has a countdown to when the new provisions for businesses regarding public signs and posters, trademarks appearing on products, and francization will come into effect in large red lettering on its website. When Bill 96 was introduced in 2022, a three-year transition period was promised but the specific rules were only announced in the summer of 2024. 'This leaves businesses with barely a few months to adjust to significant requirements, particularly in terms of signage, municipal authorizations, validation by the (Office québécois de la langue française), and the management of cultural, specialized, and short-lived products,' Rochette laments. 'They had enough time' to adapt: Roberge But Language Minister Jean-François Roberge dismissed their concerns while speaking to journalists at the National Assembly Thursday. 'I think they had enough time,' he said, adding that 'the important thing is to show the OQLF that they are moving forward, and they will follow the law.' Roberge said he is aware that not all stores are conforming to Bill 96's provisions, but 'they will in the next few months.' But the organizations say the francization process is a headache for small and medium-sized businesses. Filling out a 20-page document can take up 54 hours of work, said the RCC. Chains have to make changes in several branches, which the RCC and CFIB say is expensive and 'some are already in the millions of dollars.' They say these extra costs for stores jeopardize the competitiveness of local businesses when online retailers are not subject to equivalent constraints. 'It is not by imposing unrealistic deadlines that we strengthen French, but by focusing on clarity, predictability and the commitment of businesses to a promising collective project,'' said François Vincent, CFIB Vice-President for Quebec. The Official Opposition remains divided on the issue. Parti Québécois MNA Joël Arseneau echoed Roberge's comments, saying, 'They can do it, they can do it quickly, and they have to do it. It's a matter of respect of the official language of Quebec and they are just trying to stretch the limits, and we don't agree with that.' Interim Quebec Liberal leader Marc Tanguay called Bill 96 'a bad piece of legislation' and said the government should be listening to retailers and helping them out. 'This is not what's going to protect the French language,' he said.
Time of India
2 days ago
- Business
- Time of India
DMRC to take over desilting of covered Sunheri drain in S Delhi
New Delhi: Post-monsoon, Delhi Metro Rail Corporation (DMRC) will take over the task of desilting the Sunheri drain in south Delhi. The work, to be carried out on behalf of Municipal Corporation of Delhi (MCD), will entail cutting a portion of the covered drain and opening the RCC deck slabs to create space for desilting. The 900-metre-long, 50-metre-wide drain, which passes through Dayal Singh College and Sunheri bus depot, has not been desilted since being covered in 2010, according to DMRC. The site frequently witnesses waterlogging, impacting nearby areas like Golf Links and Bharti Nagar. A DMRC official said the project, estimated to cost Rs 35 crore, is expected to be completed within a period of one year once work commences. "We were approached for desilting a portion of the covered Sunheri nullah. A tender has been floated and work will start after all requirements, such as award of tender, allotment of funds and mobilisation of the contractor, are finalised," he said, adding that the last date for filing applications is June 4. For the coming monsoon season, MCD will continue to be responsible for the desilting and ensuring there is no waterlogging. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo Sunehari nullah is a covered RCC box drain located at Lodhi Road. The project document states, "Its upstream end starts in Dayal Singh College premises and the downstream side ends in Sunehri bus depot at Lala Lajpat Rai flyover. There are five RCC boxes of width 10 m, and the depth varies from 3.5 m to 5.5 m. The drain was constructed in 2010, and it has not been desilted so far. The work includes desilting and cleaning of all five RCC box-covered drains. " The project will also entail making openings in the RCC boxes at suitable points for access and restoration. "A small portion of the RCC box drain (50 metres) will be taken out, followed by making a bund with sandbags at both ends to divert the flow of water. Dewatering will be done, making necessary ventilation arrangements, using a crane or cranes, expert manpower with proper safety equipment for removal of sludge, and its disposal," states the document. MCD had earlier informed NGT the project will be funded by NDMC. "DMRC is to carry out the modification in the covered portion of the Sunehri Pul drain and desilt it using appropriate methodology. The NDMC chairman has been formally requested to release the funds to DMRC," it told NGT, which is currently hearing the matter related to desilting of 24 major drains with outlets in the Yamuna.
Time of India
3 days ago
- Health
- Time of India
Kin of girl who contracted HIV during blood transfusion being compensated, state govt tells Kerala high court
Kochi: The state govt has informed high court that an order has been issued sanctioning appropriate financial aid to the father of a nine-year-old girl who allegedly contracted HIV during a blood transfusion at the Regional Cancer Centre (RCC), Thiruvananthapuram, and died in 2018. Tired of too many ads? go ad free now Health and family welfare additional chief secretary Rajan Khobragade submitted in an affidavit that necessary instructions had also been issued to the revenue (disaster relief fund) department to take further steps for disbursing the financial assistance from the chief minister's disaster relief fund (CMDRF) on an urgent basis, vide order dated May 12. The affidavit was filed in response to a petition submitted by the girl's father, seeking adequate financial aid to help the family cope with the mental trauma caused by the child's untimely death and to relieve the financial burden from prolonged medical treatment. The girl, initially suspected to be suffering from leukaemia, was treated at the Medical College Hospital, Alappuzha, and later referred to RCC. She underwent 49 blood transfusions during her treatment. According to the petitioner, one of the blood donors was later found to be HIV-positive. He alleged that his daughter, who was HIV-negative at the start of treatment, contracted the infection during her treatment at RCC. However, the affidavit stated that RCC was of the considered view that the child and her family were provided full medical, psycho-social and emotional support throughout the unfortunate episode and that no lapses could be attributed to the RCC. The RCC had not recommended compensation, contending that the cause of death was not HIV infection. It was also submitted that RCC does not maintain any funds for compensating deaths or accidents arising from contingent events linked to the institution. Tired of too many ads? go ad free now The affidavit also included technical details regarding the current blood testing equipment used at RCC, highlighting the advancements in technology, including the make, model, and its superiority over the equipment in use at the relevant time.
Time of India
4 days ago
- Climate
- Time of India
Flooding at Acharya Atre station curtails Metro 3 services to Worli
Mumbai: Acharya Atre Chowk station on Mumbai's underground Metro Line 3 (Colaba–SEEPZ) was flooded following a spell of intense rain. This forced authorities to curtail operations and terminate trains at Worli. The flooding occurred at an entry/exit structure along Dr Annie Besant Road, raising concerns about the 37,000-crore corridor's waterproofing and drainage preparedness ahead of the monsoon. According to Mumbai Metro Rail Corporation Ltd (MMRCL), the incident was triggered by the collapse of a water-retaining RCC wall at the entry point. "Due to sudden and intense rainfall today, water seepage was reported at the under-construction entry/exit structure of Acharya Atre Chowk station. The incident occurred when the RCC water-retaining wall collapsed due to water ingress from an adjoining utility," the agency said in a statement. While the seepage was restricted to the construction zone, train services between Worli and Acharya Atre Chowk were suspended as a precaution. "Services between Aarey JVLR and Worli remain unaffected and are running as per schedule," the statement said. MMRCL said engineering and safety teams were on site and working "on a war footing" to fix the issue. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo "Safety remains our highest priority. Services will resume only after all systems are fully secure and operational. We regret the inconvenience caused and seek commuters' cooperation," the agency said. MMRC managing director Ashwini Bhide said average daily ridership on the line is about 45,000, and on Monday number of commuters between Worli and Aarey was about 24,000 up to 4pm. The disruption at Acharya Atre Chowk station, however, triggered sharp reactions on social media. One X user (@snakeyesV1) wrote: "Oh, the Aqua Line of Mumbai Metro, living up to its name in the most literal way possible! Who knew that a line named Aqua would actually become a swimming pool?" Another user, Manoj Arora, posted: "Promises delivered. Mumbai Metro's 'Acqua Line' is literally and truly an acqua line. Japan needs to catch up fast!" Civic activist Anil Galgali called it a result of poor planning. "The waterproofing clearly failed. The fact that rainwater entered the station premises shows the system wasn't ready. Suspending services within days of inauguration reflects lack of preparedness," he said. According to MMRC, station entrances and lifts are designed with a plinth level at least 1,200mm above road level to prevent water seepage. As a second line of defence, manual floodgates are installed at entrances and automatic gates at isolated lift locations. These are designed to withstand 500mm of water above plinth level. Each station also has an underground water tank and drainage system, equipped with automatic pumps to drain any accumulated water. Civic activist Zoru Bhathena said: "An Underground Metro line in a flood prone city like Mumbai will always be a problem. But, to see the damage caused due to this flooding is unprecedented. "
Business Wire
22-05-2025
- Business
- Business Wire
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo ®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 'We are pleased to present these preliminary findings from the phase 1b/2 STELLAR-002 study, including early signs of promising activity for zanzalintinib in combination with immune checkpoint inhibitors,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'Data emerging from this ongoing study are important to help inform further evaluation of zanzalintinib-based regimens in advanced solid tumors, including renal cell carcinoma.' Abstract 4515: Zanzalintinib + Nivolumab ± Relatlimab in Patients with Previously Untreated Clear Cell Renal Cell Carcinoma: Results from an Expansion Cohort of the Phase 1b STELLAR-002 Study Lead Author: Jad Chahoud, M.D., M.P.H., Moffitt Cancer Center, Tampa, Fla., USA Session Title: Genitourinary Cancer—Kidney and Bladder This expansion cohort of STELLAR-002 included patients with advanced clear cell RCC who received zanzalintinib in combination with either nivolumab (n=40) or fixed-dose nivolumab and relatlimab (n=40) in two non-randomized treatment arms. Patients had unresectable advanced or metastatic disease for which they received no prior systemic therapy. Intermediate- or poor-risk disease, per the International Metastatic RCC Database Consortium, accounted for 75% of patients receiving zanzalintinib in combination with nivolumab and 70% of patients receiving zanzalintinib in combination with fixed-dose nivolumab and relatlimab. At a median follow-up of 20.1 months for those receiving zanzalintinib in combination with nivolumab and 15.9 months for those receiving zanzalintinib in combination with fixed-dose nivolumab and relatlimab, the objective response rates were 63% (95% confidence interval [CI]: 46-77%) and 40% (95% CI: 25-57%), respectively. Disease control rates were 90% (95% CI: 76-97%) for both arms. The 12-month duration of response was 73.4% (95% CI: 50.0-87.1%) and 74.1% (95% CI: 39.1-90.9%), respectively. Median progression-free survival was 18.5 months (95% CI: 9.5 months-not estimable [NE]) and 13.0 months (95% CI: 7.4 months-NE), respectively. 'While significant progress has been made in advanced clear cell renal cell carcinoma, many patients still experience disease progression, and more effective therapies earlier in the treatment landscape are needed,' said Jad Chahoud, M.D., M.P.H., Associate Member, Department of Genitourinary Oncology and Medical Director of the Inpatient/Outpatient (IPOP) service at Moffitt Cancer Center in Tampa, Fla., who is presenting the findings. 'The high rate of durable responses and long progression-free survival observed for zanzalintinib in combination with nivolumab are encouraging and support further evaluation of this regimen.' Treatment-emergent adverse events (TEAEs) of any grade were reported in all patients. Grade 3/4 TEAEs occurring in at least four patients receiving zanzalintinib in combination with nivolumab included hypertension (n=13), diarrhea (n=6), aspartate aminotransferase increase (n=5), alanine aminotransferase increase (n=5) and palmar-plantar erythrodysesthesia (n=4). Grade 3/4 TEAEs occurring in at least four patients receiving zanzalintinib in combination with fixed-dose nivolumab and relatlimab included hypertension (n=6), rash (n=6), lipase increase (n=4) and pulmonary embolism (n=4). There were two grade 5 TEAEs in each arm; none were considered related to study treatment. Three patients (8%) in the zanzalintinib in combination with nivolumab arm and eight patients (20%) in the zanzalintinib in combination with fixed-dose nivolumab and relatlimab arm discontinued all study drugs for treatment-related AEs as assessed by investigator. Abstract 3101: Zanzalintinib + Nivolumab ± Relatlimab in Patients with Advanced Solid Tumors: Results from Two Dose-Escalation Cohorts of the Phase 1b STELLAR 002 Study Lead Author: Benjamin Garmezy, M.D., Sarah Cannon Research Institute, Nashville, Tenn., USA Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Monday, June 2, 1:30-4:30 p.m. CDT This analysis of STELLAR-002 included multiple cohorts of patients with advanced solid tumors who received zanzalintinib 100 mg in combination with nivolumab (n=19); zanzalintinib 60 mg in combination with fixed-dose nivolumab and relatlimab (n=24); or zanzalintinib 100 mg in combination with fixed-dose nivolumab and relatlimab (n=25). The most common cancer types for those receiving zanzalintinib in combination with nivolumab were colorectal and prostate cancers, followed by lung cancer and RCC. The most common tumor types in the zanzalintinib in combination with fixed-dose nivolumab and relatlimab cohorts were RCC, followed by prostate cancer, melanoma and colorectal cancer. The findings showed that the toxicity profile of these combinations was manageable and consistent with each monotherapy agent. Preliminary safety, efficacy and pharmacokinetic results supported selection of the 100 mg dose for zanzalintinib for the ongoing expansion cohorts. About STELLAR-002 STELLAR-002 (NCT05176483) is a global, open-label phase 1b/2 study of zanzalintinib as a single agent or in combination with nivolumab, fixed-dose nivolumab and relatlimab or nivolumab and ipilimumab in advanced solid tumors. The objective of the study is to evaluate the safety, tolerability and efficacy of zanzalintinib alone and in these combinations. The trial is divided into two parts: a dose-escalation stage and an expansion cohort stage. Expansion cohorts include patients with clear cell RCC, non-clear cell RCC, castration-resistant prostate cancer, urothelial carcinoma, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer and head and neck squamous cell carcinoma. Exelixis is sponsoring STELLAR-002, and Bristol Myers Squibb is providing nivolumab, ipilimumab and a fixed-dose combination of nivolumab and relatlimab for use in the trial. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including neuroendocrine tumors, genitourinary, colorectal and head and neck cancers. About RCC Kidney cancer is among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S. 1 Nearly 81,000 Americans will be diagnosed with kidney cancer in 2025. 1 Clear cell RCC is the most common type of kidney cancer in adults. 2 Non-clear cell RCC represents about 25% of RCC cases, with fewer treatment options available and poorer outcomes compared with clear cell RCC. 3 Advanced or metastatic RCC occurs when the cancer has spread beyond the kidney. 4 If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 18%. 5 In 2025, approximately 33,700 patients with advanced kidney cancer will require systemic therapy in the U.S., with over 21,400 patients receiving first-line treatment. 6 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the presentation of results from the Phase 1b/2 STELLAR-002 trial at ASCO 2025; the therapeutic potential of zanzalintinib in combination with either nivolumab or a fixed-dose combination of nivolumab and relatlimab in patients with previously untreated advanced clear cell RCC and advanced solid tumors; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; Exelixis' and Bristol Myers Squibb's continuing compliance with applicable legal and regulatory requirements; the potential failure of zanzalintinib in combination with either nivolumab or a fixed-dose combination of nivolumab and relatlimab to demonstrate safety and/or efficacy in future clinical testing; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; the costs of conducting clinical trials; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. Opdivo ® is a registered trademark of Bristol Myers Squibb. Opdualag™ is a trademark of Bristol Myers Squibb. ____________________ 1 Cancer Facts & Figures 2025. ACS website. Available at: Accessed May 2025. 2 What Is Kidney Cancer? ACS website. Available at: Accessed May 2025. 3 Bilen, M.A. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. Cancers (Basel). 2021;13(15):3652. 4 Kidney Cancer. Cleveland Clinic. Available at: Accessed May 2025. 5 Kidney Cancer Early Detection, Diagnosis, and Staging. ACS website. Available at: Accessed May 2025. 6 Citeline's Datamonitor Healthcare: Renal Cell Carcinoma. March 2023 (internal data on file).
